【活动】BioVerse episode 14 - The Global Trends in Biotech IPOs

Event details

Speakers intro

Andrew Lam is Managing Director and Head of Biotech Private Equity at Ally Bridge Group, a global healthcare investment management firm focused on high-impact life science innovation, where he leads therapeutic investments in private biotech companies. His investments include Arbor Bio, CARGO Therapeutics, CG Oncology, Endeavor Bio, Profound Bio, Rayze Bio, Shoreline Bio, and Sonoma Bio.  Andrew has two decades of biopharma-focused experience spanning operating roles within the industry, sellside roles in equity research and investment banking, in addition to his current buyside. Andrew holds a Pharm.D. from Long Island University and MBA from Drexel University.

Daniel Parisotto is a Managing Director on the Healthcare Banking team and joined Oppenheimer in 2019. He mostly focuses on private companies across therapeutic areas and treatment modalities.

Daniel came to Oppenheimer by way of Regeneron Pharmaceuticals where he was on the oncology strategy team for two years. Prior to Regeneron, he was on the equity research team at Guggenheim Partners where he covered big pharma and biotech companies. Daniel grew up as scientist and performed post-doctoral and pre-doctoral research at Weill Cornell and the University of Heidelberg in Germany, respectively. During this time, he published several peer-reviewed articles in various scientific journals.

Managing Director of Freedom Capital Markets managing the investment banking business with expertise in equity capital market, family office and venture investing. Prior to joining Freedom, Enna held senior positions in various global financial institutions. She was the Head of U.S. Equity Structured Issuance at Barclays Capitals. Prior to that, she was managing the Fully Funded Portfolio Risk Trading desk at Wells Fargo. In her earlier career, she also covered Structured Financing at Macquarie USA, and Fixed Income at Morgan Stanley. Her experience includes deal origination, due diligence, and execution across industry sectors on domestic and cross-border transactions. Enna holds an Executive MBA degree from Kellogg School of Management at Northwestern University, where she completed executive courses at WHU-Otto Beisheim School of Management in Germany and Hong Kong University of Science and Technology. She also has a BBA degree from Macaulay Honors College and completed her Economics degree at Sophia University in Japan.

Alex Yuen joined Jefferies as the Head of China ECM & Syndicate in December 2018. With a specialism in the healthcare and technology space, Alex spearheads all private and public capital raising activities by connecting issuers in the North Asia region and investor clients globally. On the back of the evolving geopolitical dynamics, Alex also plays an instrumental role in fostering regional collaboration by facilitating cross-border strategic discussions across sectors.

Prior to joining Jefferies, Alex worked as an Executive Director of the Asia Equity Capital & Derivatives Markets at J.P. Morgan in Hong Kong. Alex received his BBA ((Honors) from Michigan’s Ross School of Business in 2005.

Prior to joining Jefferies, Alex worked as an Executive Director of the Asia Equity Capital & Derivatives Markets at J.P. Morgan in Hong Kong. Alex received his BBA ((Honors) from Michigan’s Ross School of Business in 2005.

For over a decade, Peter Devlin has advised clients in connection with transformative financing transactions and day-to-day disclosure and compliance matters.  In particular, Pete provides strategic advice to innovative life sciences companies on a range of issues, including general corporate matters, stock exchange listing requirements, public and private financing structures, and securities law matters generally.

Pete has significant experience advising international companies on the legal and practical aspects of the public offering process in the United States. He delivers thoughtful legal expertise in a practical manner to facilitate clients’ strategic objectives. Pete serves as an advisory board member of the School of Science at Manhattan University.

Nora Luo focuses on patent prosecution and strategic intellectual property counseling in the biotechnology and pharmaceutical industries. Her practice includes preparation and prosecution of U.S. and international patent applications, patent portfolio management, due diligence evaluations, freedom-to-operate analyses, patentability evaluations, and inter partes review proceedings.

Nora has worked with established companies, start-ups, and research institutions. She has experience with a wide range of technologies, including immunotherapy (for example, antibodies, antibody drug conjugates, vaccines, cell-based therapies, CAR-T cell technology, immune checkpoint modulators), gene therapy, CRISPR technology, mRNA delivery, mRNA-based therapy, lipid nanoparticles, viral vector-based gene delivery system (for example, AAV [adeno-associated virus]), antibody engineering, RNA splicing, cancer therapeutics, virology, stem cells, neurological disorder therapeutics, high-throughput screening, genomics, diagnostic assays, anti-aging therapeutics, and small molecule pharmaceuticals.

Nora holds a Ph.D. in molecular biology from Princeton University. While at Princeton, she was awarded the American Society for Cell Biology Norton B. Gilula Award and was the recipient of the National Institute of Health Fellowship. Prior to joining Jones Day, Nora was a Damon Runyon Cancer Research fellow at The Rockefeller University. Her scientific work has been published in a number of peer-reviewed journals, including Cell and Science, and was featured in The New York Times and Nature.

Leon ‘Jun’ Tang, is the founding partner of InScienceWeTrust BioAdvisory, a business development company focused on the East-West cross-border partnerships in the pharmaceutical industry. Dr. Tang is also the founder of InScienceWeTrust Community, which has more than 2,000+ members from Asian biotech community. He is also the c-founder and host of Bioverse webinar.

Dr. Tang serves as a scientific advisor to Mianus Capital, a boutique US-based healthcare PE/VC fund currently focused on ophthalmology. He is also an advisor to BioSpark, an Asian biotech professional’s association based in Massachusetts.

Previously, Dr. Tang was a senior director of BD Search & Evaluation at Shanghai Henlius Biotech, a public biotech listed on Hong Kong Stock Exchange, a biotech sell-side analyst at Barclays Investment Bank, and a senior manager/senior analyst at the philanthropic venture fund of Cancer Research Institute of New York.

Dr. Tang has published 50+ academic papers, some of which are in Nature Reviews Drug Discovery, Lancet Oncology, Science Translational Medicine, Nature Communications, Science Advances, PNAS, etc. Dr. Tang received his bachelor’s degree from Tianjin University, master’s degree from Nankai University, PhD from Icahn School of Medicine of Mount Sinai, and postdoctoral training at Memorial Sloan Kettering Cancer Center. 

Organizers

Sponsor

Partner &Collaborators